Approval of Tivdak was based on promising results from a Phase III innovaTV 301 clinical trial, which demonstrated a 30% reduction in the risk of death in patients with recurrent or metastatic cervical cancer.
FDA Grants Full Approval to Tivdak for Treating Recurrent or Metastatic Cervical Cancer Patients Experiencing Disease Progression After Chemotherapy
Posted on by admin
1 min read
+ There are no comments
Add yours